Amgen's Bemarituzumab shows positive results in phase 3 trial for stomach cancer.

Amgen Inc. (NASDAQ: AMGN) announced positive results for a phase 3 study of Bemarituzumab for certain stomach cancers, meeting its primary endpoint by significantly improving overall survival in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer with FGFR2b overexpression. Gastric cancer is the fifth leading cause of cancer-related death globally, with nearly 1 million new cases and over 650,000 deaths annually. Bemarituzumab targets FGFR2b, a protein overexpressed in some gastric cancers, with detailed results to be presented in future meetings and an ongoing Phase 3 trial with chemotherapy and nivolumab expected to yield results in the second half of 2025.

Read more at Yahoo Finance: Amgen (AMGN) Announces Positive Results for Phase 3 Study of Bemarituzumab